ArticleTherapeutic advances in hematology2024

Successful maintenance of a sustained molecular response in CML patients receiving low-dose tyrosine kinase inhibitors.

Yan Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.